Liu, Mark C.
Chipps, Bradley
Munoz, Xavier
Devouassoux, Gilles
Bergna, Miguel
Smith, Steven G.
Price, Robert G.
Galkin, Dmitry V.
Azmi, Jay
Mouneimne, Dalal
Albers, Frank C.
Chapman, Kenneth R. http://orcid.org/0000-0002-2498-9859
Clinical trials referenced in this document:
Documents that mention this clinical trial
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
https://0-doi-org.brum.beds.ac.uk/10.1186/s12931-021-01733-9
Funding for this research was provided by:
GlaxoSmithKline foundation (204471)
Article History
Received: 25 February 2021
Accepted: 25 April 2021
First Online: 10 May 2021
Declarations
:
: The OSMO study was conducted in accordance with International Conference for Harmonization Good Clinical Practice, applicable country‐specific requirements and ethical principles outlined in the Declaration of Helsinki. All patients provided written informed consent prior to any study‐related activities. The study was approved by local ethics review boards of the participating sites.
: Not applicable.
: SGS, JA, DM, and RGP are all employees of GSK and hold stocks/shares in GSK. FCA is a former employee of GSK and holds GSK stocks/shares and is currently employed by Avillion US, Inc. DVG is a former employee of GSK and holds GSK stock/shares and is currently employed by Chiesi USA; KRC has received consulting fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, GSK, Grifols, Kamada, Novartis, Roche, and Sanofi Regeneron; has undertaken research funded by Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, GSK, Grifols, Kamada, Novartis, Roche and Sanofi; has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer Ingelheim, GSK, Grifols, Novartis and Teva. KRC is also participating in research funded by the Canadian Institutes of Health Research. GD has received personal fees or research grants from Novartis Pharma, AstraZeneca, GSK, Boehringer Ingelheim, Mundi Pharma, Vivisol, Sanofi, Chiesi, ALK, Teva, MSD and AGIR à Dom; has participated in CME activities sponsored by GSK, AstraZeneca, Novartis Pharma, Chiesi, MSD, Takeda, AGIR à Dom, Orkyn, Mundi Pharma, ALK, Stallergenes, Boehringer Ingelheim and Teva; is participating in research funded by GSK, ALK, AstraZeneca, Novartis Pharma, Boehringer Ingelheim, Vitalair, AB science, Amgen, Lilly, Sanofi, Roche and Teva. MB has received personal fees or research grants from AstraZeneca, Novartis, GSK, Boehringer Ingelheim, and Sanofi. MCL has participated in advisory board meetings for GSK, Gossamer Bio and AstraZeneca, and has received research grants from GSK, and Gossamer Bio. BC is an advisor for, has received consultancy fees from, and is on the speaker's bureau AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron and Sanofi-Genzyme. XM has received fees as a speaker, scientific advisor or participant of clinical studies for AstraZeneca, Boehringer Ingelheim, Chiesi, Faes, GSK, Menarini, MundiPharma, Novartis and Teva.